GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm

The European Medicines Agency (EMA) has asked some licence holders of GLP-1 receptor agonists for evidence into associations with suicidal ideation and self-harm as part of a review. These drugs include Ozempic (semaglutide), Saxenda (liraglutide), and Wegovy (semaglutide) and are used to treat type 2 diabetes and in weight management.The review was triggered by the Icelandic Medicines Agency in July after reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide. The authorities have so far retrieved and analysed about 150 reports of possible cases of self-injury and suicidal thoughts.The EMA’s Pharmacovigilance Risk Assessment Committee has also reviewed the available evidence from clinical trials, post-marketing surveillance, and the published literature on reported cases of suicidal thoughts and thoughts of self-harm when using GLP-1 receptor agonists.These drugs can cross the blood-brain barrier, show pharmacology reports by the manufacturers Novo Nordisk and Lilly submitted to the US Food and Drug…
Read Original Article: GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm »